PURE Bioscience Past Earnings Performance

Past criteria checks 0/6

PURE Bioscience's earnings have been declining at an average annual rate of -14.8%, while the Household Products industry saw earnings growing at 3.6% annually. Revenues have been declining at an average rate of 22.8% per year.

Key information

-14.8%

Earnings growth rate

-5.4%

EPS growth rate

Household Products Industry Growth1.5%
Revenue growth rate-22.8%
Return on equityn/a
Net Margin-183.9%
Last Earnings Update31 Oct 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How PURE Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PURE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Oct 242-340
31 Jul 242-340
30 Apr 242-440
31 Jan 242-440
31 Oct 232-440
31 Jul 232-440
30 Apr 232-440
31 Jan 232-440
31 Oct 222-440
31 Jul 222-340
30 Apr 222-340
31 Jan 222-340
31 Oct 213-340
31 Jul 214-240
30 Apr 217040
31 Jan 219140
31 Oct 208130
31 Jul 207040
30 Apr 204-240
31 Jan 202-440
31 Oct 192-550
31 Jul 192-760
30 Apr 192-770
31 Jan 192-770
31 Oct 182-880
31 Jul 182-770
30 Apr 182-880
31 Jan 182-871
31 Oct 172-771
31 Jul 172-661
30 Apr 172-561
31 Jan 172-361
31 Oct 162-1371
31 Jul 161-1471
30 Apr 161-1671
31 Jan 161-1881
31 Oct 151-971
31 Jul 151-871
30 Apr 151-881
31 Jan 151-881
31 Oct 141-991
31 Jul 141-1181
30 Apr 141-1171
31 Jan 141-1071

Quality Earnings: PURE is currently unprofitable.

Growing Profit Margin: PURE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PURE is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.

Accelerating Growth: Unable to compare PURE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PURE is unprofitable, making it difficult to compare its past year earnings growth to the Household Products industry (25.8%).


Return on Equity

High ROE: PURE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:33
End of Day Share Price 2024/12/24 00:00
Earnings2024/10/31
Annual Earnings2024/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PURE Bioscience, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keith MarkeyGriffin Securities
Guoqian ZengZacks Investment Research Inc.